Company profile
SAB Biotherapeutics, Inc.
NASDAQ: SABS · Healthcare · Biotechnology
#1166 of 1,422 Healthcare companies by revenuebottom-decile growth
EA Score
52DFH 67DQ 47GM 19SS 51
v0.1 · 65/100 weight · provisional
↑ return on assets, balance-sheet leverage · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
$13.3M
Employees
86
as of 2026-08-20
Market cap
$343.9M
as of 2026-08-20
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income$13.3M$13.3M2025
Operating income-$49.0M-$49.0M2025
Total assets$172.8M$172.8M2025
Liabilities$21.3M$21.3M2025
Equity$151.5M$151.5M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2022
By product
Grant100%
By geography
Not disclosed.
The read
What is SAB Biotherapeutics, Inc.’s revenue?
SAB Biotherapeutics, Inc. booked $0 in FY2025 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a Infinity% net margin.
Peers · Healthcare
Compass Therapeutics, Inc.50DRocket Pharmaceuticals, Inc.53DPalisade Bio, Inc.71BInhibikase Therapeutics, Inc.43DZentalis Pharmaceuticals, Inc.40DEledon Pharmaceuticals, Inc.39DNeighbors
Miami-Dade →Key facts
CEOSamuel J. Reich
SectorHealthcare
IndustryBiotechnology
HeadquartersMiami Beach, FL
ExchangeNASDAQ: SABS
Employees86
IPO date2021-02-09
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.